Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Medicine and Health Sciences
Ls There Any Risk Of A Withdrawal Syndrome Associated With Abrupt Discontinuation Of Selective Serotonin Reuptake Inhibitors?, Rene A. Endow, Mary Gutierrez, Michael Z. Wincor
Ls There Any Risk Of A Withdrawal Syndrome Associated With Abrupt Discontinuation Of Selective Serotonin Reuptake Inhibitors?, Rene A. Endow, Mary Gutierrez, Michael Z. Wincor
Pharmacy Faculty Articles and Research
"With the availability of the newer selective serotonin reuptake inhibitors (SSRis), concern over a 'cholinergie rebound' seemed unnecessary since these agents demonstrate little or no anticholinergic activity. However, a review of the literature indicates that there may be other withdrawal symptoms associated with discontinuation of the SSRis. The time course and, perhaps to a lesser extent, the frequency of these symptoms appear to be correlated with the elimination half-lives of the agents."
What Is The Risk Of Teratogenicity With The Use Of Selective Serotonin Reuptake Inhibitors During Pregnancy?, Michael Z. Wincor, Mary Gutierrez, Ann Nguyen
What Is The Risk Of Teratogenicity With The Use Of Selective Serotonin Reuptake Inhibitors During Pregnancy?, Michael Z. Wincor, Mary Gutierrez, Ann Nguyen
Pharmacy Faculty Articles and Research
"The lifetime prevalence of major depressive disorder in women is 10 to 25%, with an average age of onset in the mid-20s.1 Over the nine years that the selective serotonin reuptake inhibitors (SSRis) have been available, for many prescribers, they have become first-line agents in the treatment of depression. In addition, sorne of them are also being used in the treatment of obsessive- compulsive disorder and panic disorder. In light of these facts, itis not unlikely that women of childbearing age would be treated with one of the SSRis. In considering the risks of exposing a fetus to an SSRI, …